Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heavy chain disease.

Thomas E Witzig1, Dietlind L Wahner-Roedler

  • 1Division of Hematology, Mayo Clinic and Mayo Foundation, 200 SW First Street, Rochester, MN 55905, USA. witzig@mayo.edu

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary

Heavy chain diseases (HCDs) are rare B-cell cancers where malignant cells produce immunoglobulin heavy chains without light chains. Alpha-HCD presents as intestinal malabsorption, while gamma- and mu-HCD are associated with non-Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Battlefield Acupuncture in Emergency Department Settings: A Systematic Review of Randomized Controlled Trials.

Journal of integrative and complementary medicine·2026
Same author

Association of hormone therapy and outcomes in COVID-19.

Menopause (New York, N.Y.)·2025
Same author

Effect of Reiki on Measures of Well-Being in Low-Income Patients with Mental Health Diagnoses.

Global advances in integrative medicine and health·2025
Same author

Use of Complementary and Integrative Medicine Among Low-Income Persons With Mental Health Disorders.

Mayo Clinic proceedings. Innovations, quality & outcomes·2025
Same author

Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome.

Leukemia & lymphoma·2024
Same author

Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance.

Hematological oncology·2024

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Heavy chain diseases (HCDs) are rare B-cell malignancies characterized by monoclonal immunoglobulin heavy chain (HC) production without associated light chains.
  • Three types exist: IgA (alpha-HCD), IgG (gamma-HCD), and IgM (mu-HCD), defined by the HC class produced.

Purpose of the Study:

  • To describe the characteristics, diagnosis, and treatment of heavy chain diseases.
  • To differentiate alpha-HCD from gamma- and mu-HCD based on clinical presentation and association with other B-cell malignancies.

Main Methods:

  • Review of existing literature and case studies on heavy chain diseases.
  • Analysis of diagnostic criteria and treatment strategies for different HCD subtypes.

Main Results:

  • Alpha-HCD is the most common type, often presenting as intestinal malabsorption in young adults from Mediterranean regions.
  • Gamma- and mu-HCD are rare, typically found in patients with B-cell non-Hodgkin's lymphoma (NHL) producing abnormal HC, and may be associated with monoclonal gammopathy of undetermined significance (MGUS).
  • Treatment for alpha-HCD involves antibiotics, nutrition, hygiene, and potentially chemotherapy for aggressive forms or lack of response.
  • Chemotherapy is indicated for patients with gamma- or mu-HCD associated with NHL or MGUS.

Conclusions:

  • Heavy chain diseases require specific diagnostic and treatment approaches based on the subtype.
  • Screening serum and urine in lymphoplasmacytoid NHL patients may improve detection of gamma- and mu-HCD.
  • Early diagnosis and appropriate treatment, including chemotherapy for certain subtypes, are crucial for managing these rare B-cell malignancies.

Related Experiment Videos